Investor Presentaiton

R&D investor presentation 13 The icodec phase 3 programme will aim to demonstrate superiority on HbA₁ and time in range Insulin icodec phase 3 programme Insulin icodec versus insulin 970 people with type 2 diabetes and insulin naive glargine Icodec (open label) Insulin glargine U100 (open label) 78-week treatment 6 clinical trials enrolling approximately 4,400 people Both type 1 and type 2 diabetes Add-on to OADS, GLP-1s, switching from basal as well as switching from basal- bolus Initiation expected in Q4 2020 Details Add on to OADs and GLP-1s Primary endpoint • Change in HbA1c at week 52 Confirmatory secondary endpoint Time in target range from week 48 to week 52 Insulin icodec versus basal analogues Icodec (open label) Basal analogues (open label) 52-week treatment 1,096 people with type 2 diabetes and insulin naive Details Randomised controlled trial with real world elements Effectiveness of icodec in combination with any non-insulin anti-diabetic medicine in a primary care setting Primary endpoint Change in HbA1c at week 52 OAD: Oral anti-diabetic

View entire presentation